|Dr. Luke B. Evnin||Co-Founder & Chairman||N/A||N/A||1963|
|Dr. Gerald McMahon||Pres, CEO & Director||654.1k||N/A||1955|
|Dr. Holger Wesche Ph.D.||Chief Scientific Officer||419.47k||N/A||1968|
|Dr. Natalie R. Sacks||Chief Medical Offer||196.8k||N/A||1965|
|Ms. Georgia L. Erbez||Chief Financial Officer||N/A||N/A||1967|
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.